| Panpan Zhang,Lin Shen. Circulating biomarkers for nonfunctional gastroenteropancreatic neuroendocrine neoplasm: Where do we stand?. Oncol Transl Med, 2017, 3: 15-19. |
| 非功能性胃肠胰神经内分泌肿瘤循环生物标志物研究进展 |
| Circulating biomarkers for nonfunctional gastroenteropancreatic neuroendocrine neoplasm: Where do we stand? |
| Received:August 26, 2016 Revised:January 31, 2017 |
| DOI：10.1007/s10330-016-0186-6 |
| 中文关键词: 神经内分泌肿瘤；生物标志物；循环肿瘤细胞；Netest；microRNA |
| 英文关键词: neuroendocrine neoplasm; biomarker; circulating tumor cells; NETest; microRNA |
| 基金项目: |
| Author Name | Affiliation | E-mail | | Panpan Zhang | Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of GI Oncology, Peking University, School of Oncology, Beijing Cancer Hospital & Institute, Beijing 100142, China | zppxmu@163.com | | Lin Shen* | Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of GI Oncology, Peking University, School of Oncology, Beijing Cancer Hospital & Institute, Beijing 100142, China | linshenpku@163.com |
|
| Hits: 10870 |
| Download times: 12410 |
| 中文摘要: |
| 胃肠胰神经内分泌肿瘤是起源于肽能神经元和神经内分泌细胞的异质性肿瘤，临床表现、生物学行为及预后存在明显差异。非功能性GEP-NEN多见，发病隐匿且缺乏特异的生物标志物，多数病人确诊时已出现局部进展或远处转移。此外，该类肿瘤的可选治疗方案有限，目前应用的组织生物标志物及影像学检查存在诸多局限性，难以满足GEP-NENs临床管理需求。因此亟须对GEP-NEN进行精准诊断、疗效评价及进展监测的新型生物标志物。组织活检的生物标志物可提供上述信息，但重复活检在临床中可操作性差，难以及时反馈治疗效果及疾病进展。相比之下，包括NETest、循环肿瘤细胞、microRNA等在内的液体活检循环生物标志物更为有效、简便，可重复进行以提供实时信息，具有较大的应用临床的潜能。 |
| 英文摘要: |
| Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) encompass a heterogeneous group of
tumors associated with variable presentations, growth rates, and prognoses. The majority of GEP-NENs are
nonfunctional, and their diagnosis remains challenging given the often subtle and variable clinical manifestations
of these tumors. As a consequence, GEP-NENs are often recognized at an advanced stage; indeed,
most patients with nonfunctional GEP-NENs exhibit metastatic disease at diagnosis. Lack of treatment options
as well as limitations in currently available imaging modalities and biomarkers make it challenging to
manage NENs. Thus, novel biomarkers are needed to provide high sensitivity and specificity for minimum
disease detection and to predict treatment efficacy and prognosis. Although tissue-based biomarker data
can provide such information, circulating biomarkers such as NETests, circulating tumor cells, and microRNAs,
are superior owing to their easy accessibility and the ability for repeated real-time sampling. |
|
View Full Text
Download reader HTML全文 |
| Close |
|
|
|